Avanir Pharmaceuticals News
Most Popular Avanir Pharmaceuticals Story
Avanir stock boosted by promising Zenvia data
A Phase III trial of Avanir Pharmaceuticals' closely-watched drug Zenvia showed that the drug relieved Pseudobulbar affect (PBA) in a subset of multiple sclerosis patients, sending Avanir's stock up Read more...
Latest Headlines
- November 1, 2010
- November 10, 2009
- October 9, 2009
- October 7, 2009
- August 11, 2009
- March 27, 2008
- November 9, 2006
- October 30, 2006
- August 8, 2006
- May 24, 2006
- May 22, 2006
- May 9, 2006
- September 21, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
